Research Topics
| J G JurcicSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Immunotherapy for acute myeloid leukemiaJoseph G Jurcic
Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 458, New York, NY 10021, USA
Curr Oncol Rep 7:339-46. 2005..T-cell recognition of peptide antigens presented on the cell surface in combination with major histocompatibility complex antigen provides another potentially promising approach for the treatment of AML...
What happened to anti-CD33 therapy for acute myeloid leukemia?Joseph G Jurcic
Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Curr Hematol Malig Rep 7:65-73. 2012....
Ab therapy of AML: native anti-CD33 Ab and drug conjugatesJ G Jurcic
Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, New York, USA
Cytotherapy 10:7-12. 2008....
Diagnosis and treatment of acute promyelocytic leukemiaJoseph G Jurcic
Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Oncol Rep 9:337-44. 2007..The lessons learned from APL have broad applications to other forms of leukemia and to cancer in general, whereby molecularly targeted therapy is directed to specifically defined subgroups...
Monitoring PML-RARalpha in acute promyelocytic leukemiaJoseph G Jurcic
Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Oncol Rep 5:391-8. 2003..APL provides a useful model in which therapy is targeted to an underlying genetic aberration and treatment is adapted based on monitoring of residual disease...
Targeted alpha particle immunotherapy for myeloid leukemiaJoseph G Jurcic
Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
Blood 100:1233-9. 2002..This study demonstrates the safety, feasibility, and antileukemic effects of (213)Bi-HuM195, and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans...
Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemiaJ G Jurcic
Leukemia, Hematology, and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Blood 98:2651-6. 2001..Conversely, a confirmed positive test is highly predictive of relapse...
Advances in immunotherapy of hematologic malignancies: cellular and humoral approachesJ G Jurcic
Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA
Curr Opin Hematol 7:247-54. 2000..Clinical trials exploiting the new understanding of the T cell immunology are underway...
Antibody therapy of acute myelogenous leukemiaJ G Jurcic
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Biother Radiopharm 15:319-26. 2000..Additionally, directed chemotherapy using an anti-CD33-calicheamicin conjugate (CMA-676) has produced remissions in patients with relapsed AML...
Antibody immunotherapy for leukemiaJ G Jurcic
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
Curr Oncol Rep 2:114-22. 2000..Targeted alpha particle therapy offers the possibility of selective tumor cell kill while sparing surrounding normal cells. Antibody-drug conjugates and immunotoxins have produced complete remissions in leukemia...
Antibody therapy for residual disease in acute myelogenous leukemiaJ G Jurcic
Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
Crit Rev Oncol Hematol 38:37-45. 2001..Antibody-drug conjugates, such as gemtuzumab ozogamicin, composed of a humanized anti-CD33 mAb and calicheamicin, have produced complete remissions in patients with relapsed AML and are likely to be active in the postremission setting...
Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemiaK S Kolbert
Department of Medical Physics Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 42:27-32. 2001..CONCLUSION: Rate images make it possible to succinctly display kinetic information about an agent's behavior over the entire acquired image...
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemiasJ M Burke
Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY, USA
Bone Marrow Transplant 32:549-56. 2003..These studies show the feasibility of adding CD33-targeted radioimmunotherapy to a standard BMT preparative regimen; however, randomized trials will be needed to prove a benefit to intensified conditioning with radioimmunotherapy...
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesNicole Lamanna
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 27:491-7. 2009..In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold. Subsequently, rituximab was added to this regimen (F-->C-->R)...
Monoclonal antibody therapy of APLP G Maslak
Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
Curr Top Microbiol Immunol 313:205-19. 2007..The preliminary results have been promising, and further development of this modality as an effective adjunct to existing treatment regimens will most certainly occur in the near future...
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trialAzra Raza
St Vincent s Comprehensive Cancer Center, New York, NY, USA
Leuk Lymphoma 50:1336-44. 2009..In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity...
The promise of targeted {alpha}-particle therapyDeborah A Mulford
Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Nucl Med 46:199S-204S. 2005..Treatment of patients with less-advanced disease and, ultimately, randomized trials comparing targeted alpha-particle therapy with standard approaches will be required to determine the clinical utility of this approach...
Radioimmunotherapy for acute leukemiaJohn M Burke
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Control 9:106-13. 2002..In this article, we summarize the role of radioimmunotherapy in the treatment of leukemia...
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemiaMark A Weiss
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Cornell University Medical College, New York, NY 10021, USA
J Clin Oncol 21:1278-84. 2003..Of the purine analogs active in CLL, pentostatin may be least myelosuppressive. We hypothesized that combining pentostatin with cyclophosphamide would have less myelotoxicity than combinations using other purine analogs...
Acute myeloid leukemia with t(5;18)(q35;q21)E S Wang
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
Cancer Genet Cytogenet 127:71-3. 2001..Possible molecular mechanisms underlying the pathogenesis of the disease are discussed...
Antibody-based treatment of acute myeloid leukaemiaDeborah A Mulford
Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 458, New York, NY 10021, USA
Expert Opin Biol Ther 4:95-105. 2004....
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemiaNicole Lamanna
Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:1575-81. 2006..Based on these results, we are currently studying PCR as initial therapy for patients with CLL...
Radioimmunotherapy of leukemiaJohn M Burke
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NewYork 10021, USA
Adv Pharmacol 51:185-208. 2004
Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericinTimothy B Aliff
Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 97:1025-32. 2003..Although an absolute assessment of efficacy is limited by the design of this study, encouraging outcomes were noted for many patients. The authors plan to evaluate this regimen further in a randomized clinical trial...
Antibody therapy in acute myeloid leukemia: current status and future directionsJohn M Burke
Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Lymphoma 2:S12-8. 2002..Directed chemotherapy using the anti-CD33-calicheamicin conjugate gemtuzumab ozogamicin (Mylotarg) has produced remissions in patients with relapsed AML...
A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemiaMark A Weiss
Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cancer 95:581-7. 2002..This regimen may be most suitable for patients who can undergo potentially curative allogeneic bone marrow transplantation if they achieve a complete response...
